Rapamycin is an effective inhibitor of human renal cancer metastasis

Kidney International

Volumn 63, Issue 3, 2003, Pages 917-926

  Luan, Fu L ^a   Ding, Ruchuang ^a   Sharma, Vijay K ^a   Chon, W James ^a   Lagman, Milagros ^a   Suthanthiran, Manikkam ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Box 3 ^*  (United States)

Author keywords

Cyclosporine; Rapamycin; Renal cancer

Indexed keywords

CYCLOSPORIN; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DISEASE SIMULATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY METASTASIS; LUNG METASTASIS; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; SCID MOUSE; SPECIES COMPARISON; SURVIVAL TIME; TARGET CELL; TUMOR GROWTH;

EID: 0037336853     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00805.x     Document Type: Article

References (30)

1. BORING CC, SQUIRES TS, TONG T, MONTGOMERY S: Cancer statistics, 1994. CA Cancer J Clin 44:7-26, 1994
2. MOTZER RJ, BANDER NH, NANUS DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
3. FLANIGAN RC, SALMON SE, BLUMENSTEIN BA, et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659, 2001
4. LINEHAN WM, LERMAN MI, ZBAR B: Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273:564-570, 1995
5. ILIOPOULOS O, KIBEL A, GRAY S, KAELIN WG, JR: Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1:822-826, 1995
6. ANANTH S, KNEBELMANN B, GRUNING W, et al: Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59:2210-2216, 1999
7. KNEBELMANN B, ANANTH S, COHEN HT, SUKHATME VP: Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58:226-231, 1998
8. TAKAHASHI A, SASAKI M, KIM SJ, et al: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54:4233-4237, 1994
9. NICOL D, HII SI, WALSH M, et al: Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 157:1482-1486, 1997
10. SIEMEISTER G, WEINDEL K, MOHRS K, et al: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299-2301, 1996
11. LUAN FL, HOJO M, MALUCCIO M, et al: Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73:1565-1572, 2002
12. KLIEM V, KOLDITZ M, BEHREND M, et al: Risk of renal cell carcinoma after kidney transplantation. Clin Transplant 11:255-258, 1997
13. DOUBLET JD, PERALDI MN, GATTEGNO B, et al: Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 158:42-44, 1997
14. SHEIL AG, DISNEY AP, MATHEW TH, AMISS N: De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 25:1383-1384, 1993
15. POPE JC, KOCH MO, BLUTH RF: Renal cell carcinoma in patients with end-stage renal disease: a comparison of clinical significance in patients receiving hemodialysis and those with renal transplants. Urology 44:497-501, 1994
16. PENN I: Primary kidney tumors before and after renal transplantation. Transplantation 59:480-485, 1995
17. HOJO M, MORIMOTO T, MALUCCIO M, et al: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530-534, 1999
18. YAGODA A, ABI-RACHED B, PETRYLAK D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22:42-60, 1995
19. MOTZER RJ, MAZUMDAR M, BACIK J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
20. TANGUAY S, SWANSON DA, PUTNAM JB, JR: Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery. J Urol 156:1586-1589, 1996
21. WALTHER MM, YANG JC, PASS HI, et al: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158:1675-1678, 1997
22. DILLING MB, DIAS P, SHAPIRO DN, et al: Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 54:903-907, 1994
23. WECHSEL HW, BICHLER KH, FEIL G, et al: Renal cell carcinoma: Relevance of angiogenetic factors. Anticancer Res 19:1537-1540, 1999
24. THELEN P, HEMMERLEIN B, KUGLER A, et al: Quantification by competitive quantitative RT-PCR of VEGF-A121 and VEGF-A165 in renal cell carcinoma. Anticancer Res 19:1563-1565, 1999
25. YU Y, SATO JD: MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 178:235-246, 1999
26. YIN JJ, SELANDER K, CHIRGWIN JM, et al: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197-206, 1999
27. GUBA M, VON BREITENBUCH P, STEINBAUER M, et al: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8:128-135, 2002
28. MAJEWSKI M, KORECKA M, KOSSEV P, et al: The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 97:4285-4290, 2000
29. DOUROS J, SUFFNESS M: New antitumor substances of natural origin. Cancer Treat Rev 8:63-87, 1981
30. CP E, SEHGAL SN, VEZINA C: Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 37:1231-1237, 1984